Shares of Aerie Pharmaceuticals (AERI) are up 23% premarket on modest volume in response to its announcement of successful results for its glaucoma drug candidate Roclatan in a 297-patient 28-day Phase 2b clinical trial. Roclatan is a combination of the company's triple-action Rhopressa and latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug.
The once-daily eyedrop Roclatan achieved its primary endpoint of statistically significant superiority over each of its components on day 29. Mean diurnal intraocular pressures (IOP) in the Roclatan test group dropped 34% compared to the latanoprost cohort. The efficacy of Roclatan exceeded that of latanoprost across each time point evaluated.
Plans for a Phase 3 study will be begin immediately.
Management will hold a conference today at 8 am EDT to discuss the results.